THU0297 Evaluation of cardiovascular risk factors among patients with psoriasis, psoriatic arthritis and peripheral spondyloarthritis
Authors: M.R. Camacho-Sánchez, C. López-Medina, L. Bautista-Aguilar, L. Ladehesa-Pineda, L. Pérez-Sánchez, I. Gómez-García, A.J. Vélez García-Nieto, E. Collantes-Estévez, M.D. López-Montilla
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> It is well known that the prevalence of Cardiovascular Risk Factors (CVRF) in patients with Psoriatic Arthritis (PsA) is higher than in the general population<sup>1</sup>. However, there is a lack of studies comparing PsA against Psoriasis without arthritis, and also against peripheral Spondyloarthritis (SpA). <h3>Objectives</h3> a) To compare the prevalence of CVRF among patients with PsA, Psoriasis without arthritis and peripheral SpA without Psoriasis; and b) to evaluate the association between CVRF and the presence of arthritis and/or Psoriasis. <h3>Methods</h3> A cross-sectional, observational and unicenter study in which clinical, analytical and demographic data from 300 patients were analysed. Patients were divided into four groups: PsA, Psoriasis without arthritis, peripheral SpA without Psoriasis and controls. Patients with PsA and peripheral SpA met CASPAR and peripheral ASAS criteria, respectively. Hypertension, Diabetes (T2DM) and Dyslipidemia were evaluated among the four groups by using the chi-square test. In order to evaluate whether CVRF could be explained by the presence of arthritis or Psoriasis, we divided patients (by excluding control groups) in arthritis/no arthritis and Psoriasis/no Psoriasis. Univariate and multivariate logistic regressions adjusted by sex and age were performed in order to determine variables independently associated with the presence of these three CVRF. <h3>Results</h3> Among the 300 patients included in the analysis, 89 (29.7%), 35 (11.7%) and 87 (29%) patients reported Hypertension, T2DM and Dyslipidemia, respectively. Regarding classification, 61 (20.3%) patients, 100 (33.3%), 100 (33.3%) and 39 (13.0%) patients were classified as control group, Peripheral SpA without Psoriasis, PsA and Psoriasis without arthritis, respectively. Patients from the control group showed significantly lower prevalence of Hypertension and Dyslipidemia against the other three groups (p&lt;0.05); however, there were no differences between Peripheral SpA group, PsA and Psoriasis without arthritis regarding CVRF. Patients with arthritis showed similar prevalence of CVRF than those without arthritis, as well as patients with Psoriasis vs. no Psoriasis. Univariate analysis showed that Hypertension is significantly associated (p&lt;0.05) to AINEs intake [OR 1.79 (95%CI 1.06–2.99)] as well as with disease duration [OR 1.02 (95%CI 1.01–1.05)]; however, the multivariate analysis adjusted by age and sex did not show significant differences. Regarding T2DM and dyslipidemia, the presence of arthritis or Psoriasis was not associated with the development of these comorbidities. <h3>Conclusions</h3> Our data suggest that the prevalence of CVRF among patients with Psoriasis, PsA and peripheral SpA are similar, although it is higher than in the general population. The presence of Hypertension in these patients is associated with the use of NSAIDs; however, greater new studies would be necessary in order to determine specific associations. <h3>Reference</h3> [1] Kharaishi M, Aslanov R, Rampakakis E, et al. Prevalence of cardiovascular risk factors in patients with psoriatic arthritis. Clin Rheumatol. 2014;33(10):1495–500. <h3>Disclosure of Interest</h3> None declared